Mitigating risk in academic preclinical drug discovery.
Mitigating risk in academic preclinical drug discovery.
复制标题
DOI：
10.1038/nrd4578
复制
发表时间：
2015-04
期刊：
影响因子：
--
通讯作者：
Walters MA
中科院分区：
文献类型：
--
作者：
Dahlin JL;Inglese J;Walters MA
The number of academic drug discovery centres has grown considerably in recent years, providing new opportunities to couple the curiosity-driven research culture in academia with rigorous preclinical drug discovery practices used in industry. To fully realize the potential of these opportunities, it is important that academic researchers understand the risks inherent in preclinical drug discovery, and that translational research programmes are effectively organized and supported at an institutional level. In this article, we discuss strategies to mitigate risks in several key aspects of preclinical drug discovery at academic drug discovery centres, including organization, target selection, assay design, medicinal chemistry and preclinical pharmacology.
登录
查看更多内容
影响因子：
7.3
作者：
Abou-Gharbia, Magid;Childers, Wayne E.
通讯作者：
Childers, Wayne E.
DOI：
10.2174/1386207317666140109122033
发表时间：
2014-03-01
影响因子：
1.8
作者：
Dosa, Peter I.;Georg, Gunda I.;Wong, Henry L.
通讯作者：
Wong, Henry L.
影响因子：
17.1
作者：
Fishman, Mark C.
通讯作者：
Fishman, Mark C.
影响因子：
64.8
作者：
通讯作者：
--
影响因子：
4.2
作者：
Dahlin JL;Walters MA
通讯作者：
Walters MA